BNP and hsCRP as Predictors in Chest Pain Patients
Author Information
Author(s): Brügger-Andersen Trygve, Pönitz Volker, Staines Harry, Pritchard David, Grundt Heidi, Nilsen Dennis WT
Primary Institution: Institute of Medicine, University of Bergen, Bergen, Norway
Hypothesis
Does the combined use of BNP and hsCRP improve risk stratification for mortality and cardiovascular events in chest pain patients?
Conclusion
BNP is a useful biomarker for predicting long-term mortality in chest pain patients, while hsCRP does not improve survival risk stratification.
Supporting Evidence
- 129 patients died during the 24-month follow-up.
- BNP levels were significantly higher in patients who died compared to survivors.
- HsCRP did not provide prognostic information for all-cause mortality.
Takeaway
Doctors can use BNP levels to help figure out how likely it is that a patient with chest pain will have serious problems later on, but hsCRP isn't as helpful for that.
Methodology
The study was a single-center prospective follow-up study involving 871 patients with chest pain and potential acute coronary syndromes, with blood samples taken at admission and follow-up conducted over 24 months.
Limitations
The study was conducted at a single center and had a high mortality rate, which may limit generalizability.
Participant Demographics
Patients were unselected and included a high percentage of elderly individuals with comorbidities.
Statistical Information
P-Value
0.000
Confidence Interval
95% CI, 1.97–13.38
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website